The epidemiology, inflammatory pathophysiology, diagnosis, and treatment of diabetic macular edema are discussed during Inflammatory Eye Disease Week.

CLARITY program data show significantly longer time to treatment failure and higher rates of steroid-free quiescence vs placebo.

Uveitis is uncommon, but it causes a disproportionate share of visual morbidity.

Murtaza K. Adam, MD, shares pearls on haptic docking, patient selection, and preventing complications with the Yamane technique.

Spectacle lenses with highly aspherical lenslets are safe and effective for reducing myopia progression in US children.

CHMP backs Accord Healthcare’s Lucentis biosimilar Fovlussea for nAMD, DMO, RVO and CNV ahead of an EC decision.

Andrew G. Lee, MD, and Drew Carey, MD, break down the link between optic neuritis and uveitis in central nervous system demyelinating disease.

Enrollment in the licaminlimab trial closed above target, with two-thirds of 176 patients carrying a TNFR1 variant associated with stronger treatment response. Topline data are expected around year-end 2026.